Galactosyltransferase activity was assayed in sera from 58 patients with various types of cancer. On discontinuous polyacrylamide gel electrophoresis a slow-moving peak of galactosyltransferase activity (isoenzyme II) was found to be present in the serum of 43 Galactosyltransferase activity has been identified with intracellular membranes, primarily the Golgi membrane fraction (1). Recent reports have also demonstrated the presence of galactosyltransferase activity on the cell surface membrane of :various cell types which include rat intestinal crypt cells (2), human fetal cells (2), and chemically induced rat tumor cells (3). Bosmann and Hall (4) reported elevated levels of sialyltransferases in homogenates of tumor cells from human breast and colon. Kessel and Allen reported elevated sialyltransferase activity in the plasma of cancer patients (5). Galactosyltransferase activity has also been detected in rat and human serum as a soluble activity (6, 7), but the total activity was not previously found to be elevated in cancer patients unless liver disease was also present (8). However, by means of discontinuous polyacrylamide gel electrophoresis Podolsky and Weiser were able to detect in cancer patients a slower moving peak of activity that separated well from the major, more anodally directed peak of activity found in all patients (9). The present report describes the cancer patients who were tested for serum galactosyltransferase isoenzymes, compares them with disease and normal controls, and examines possible clinical and laboratory correlations with serum levels of these isoenzymes.
subjects. There was no correlation between the presence of this electrophoretically distinct isoenzyme and total serum galactosyltransferase activity, alkaline phosphatase, levels of carcinoembryonic antigen, or blood type. However, patients with widespread metastases had significantly higher isoenzyme II levels than those with no metastases or with limited local spread. Further studies will be necessary to evaluate the clinical usefulness of this serum galactosyltransferase isoenzyme in the diagnosis and monitoring of patients with neoplastic disease.
Galactosyltransferase activity has been identified with intracellular membranes, primarily the Golgi membrane fraction (1) . Recent reports have also demonstrated the presence of galactosyltransferase activity on the cell surface membrane of :various cell types which include rat intestinal crypt cells (2) , human fetal cells (2) , and chemically induced rat tumor cells (3) . Bosmann and Hall (4) reported elevated levels of sialyltransferases in homogenates of tumor cells from human breast and colon. Kessel and Allen reported elevated sialyltransferase activity in the plasma of cancer patients (5) . Galactosyltransferase activity has also been detected in rat and human serum as a soluble activity (6, 7) , but the total activity was not previously found to be elevated in cancer patients unless liver disease was also present (8) . However, by means of discontinuous polyacrylamide gel electrophoresis Podolsky and Weiser were able to detect in cancer patients a slower moving peak of activity that separated well from the major, more anodally directed peak of activity found in all patients (9) . The present report describes the cancer patients who were tested for serum galactosyltransferase isoenzymes, compares them with disease and normal controls, and examines possible clinical and laboratory correlations with serum levels of these isoenzymes.
MATERIALS AND METHODS
Biochemical Assays. Galactosyltransferase activity in whole serum was measured as previously described (9) . The glycoprotein acceptor used for this enzyme assay was fetuin minus its terminal sialic acid and penultimate galactose residues (10) .
Polyacrylamide gel electrophoresis of sera and detection of galactosyltransferase activity from slices of polyacrylamide gels were performed by the method of Podolsky and Weiser (9) . It was observed that the cancer-associated cathodal peak of activity (isoenzyme II) could not be detected * To whom reprints should be addressed. unless the gel reagents were first re-crystallized. N-acetylglucosamine (1 mM) was added to the gel eluting solution to stabilize the enzyme; it did not affect galactosyltransferase activity with fetuin acceptor. Polyacrylamide electrophoresis appeared to separate two peaks of galactosyltransferase (fetuin) activity which entered the gel. No galactosyltransferase activity with endogenous acceptor was detected. The major peak, which was found in all sera, was the more anodal one, while the smaller peak (isoenzyme II) was near the origin but separated from the activity remaining at the origin (9 
RESULTS
Measurement of total serum galactosyltransferase activity from patients with carcinoma demonstrated a mean level of activity higher than in normal control subjects or patients with nonmalignant disorders, but the increase was not statistically significant (Fig. 1) . After polyacrylamide electrophoresis the major normal peak, isoenzyme I, was also found in greater amounts in sera from patients with carcinoma (Fig. 2) but this, again, was not statistically significant. However, the presence of isoenzyme II was only detected in sera of patients with cancer ( Fig. 2 and Table 1 ) with two exceptions to date ( Table 2) . One of these exceptions was an 87-year-old woman with profound anemia who demonstrated an "applei. core" radiological sign in the sigmoid colon on barium enema that did not change its appearance after glucagon administration. Laparotomy apparently only showed diverticulae, and no tissue was removed for pathologic examination. The other exception was a patient with active nontropical sprue, a condition known to be associated with increased intestinal epithelial cell turnover (see below).
Clinical data of patients whose sera demonstrated isoenzyme II are presented in Table 1 . Most tumors were adenocarcinomas of entodermally derived tissue, although isoenzyme II was also found in several patients with squamous cell carcinoma. One patient with isoenzyme II had a colonic adenocarcinoma which extended into the colonic fat but with negative nodes. In this patient, isoenzyme II was demonstrated in two separate sera preoperatively but was not de' tectable after removal of the tumor.
To date we have observed flo correlation with blood type or with the levels of serum alkaline phosphatase, transaminase, or bilirubin. However, the level of galactosyltransferase isoenzyme II activity appeared to correlate with widespread metastases, as shown in Fig. 3 (P < 0.001).
Of 17 patients with no detectable isoenzyme II, eleven also had tumors of entodermally derived organs (Table 1) . Sera from 22 normal, non-age matched controls (laboratory personnel) were evaluated for presence of galactosyltransferase isoenzymes I and II. While all contained the normal isoenzyme I, we were unable to detect the slow moving isoenzyme II in these control sera.
As with normal controls, none of the disease controls demonstrated isoenzyme II (Table 2 ) with the two exceptions mentioned above.t These disease controls included two patients (first two listed in Table 2 ) with prior histologically proven carcinoma who at the time of this study had no evidence of tumor. The other disease controls included patients with various forms of liver disease, pancreatitis, cholecystitis, inflammatory bowel disease, and peptic ulcer. Three patients with uremia did demonstrate increased total galactosyltransferase activity but no evidence of isoenzyme II.
In six patients levels of carcinoembryonic antigen were determined at the same time as the galactosyltransferase isoenzymes were assayed. Four had "normal" levels of this antigen but had evidence of galactosyltransferase isoenzyme II activity; in the two others, isoenzyme II was not detectable but their serum revealed high carcinoembryonic antigen levels. Thus, to date there has been no consistent correlation between these two assays, suggesting that carcinoembryonic ) antigen and galactosyltransferase isoenzyme II represent different chemical entities.
DISCUSSION
The enzymes known generically as glycosyltransferases participate in the biosynthesis of complex carbohydrates. They are commonly found as membrane-bound enzymes within the interior of the cell; the Golgi membrane may, in fact, be identified biochemically by the presence of these glycosyltransferases (1). The function of adding sugars to proteins is not clear, although the nature of the terminal sugar appears to be important in the control of secretion and in the clearance of circulating glycoproteins (11) . A significant portion of serum proteins are glycoproteins and the biosynthesis of ABO blood group substances also requires sugar additions through the action of glycosyltransferases (12) . Although some glycosyltransferases appear to be membrane-associated enzymes when prepared from tissue homogenates, these transferases have also been detected as soluble enzymes in various body fluids, including rat and human serum (6, 7) .
Human serum galactosyltransferase has been previously studied by Kim et al. (7), who demonstrated increased activity of total serum galactosyltransferase in patients with liver disease. They did not find any increased levels in patients with cancer unless the liver was involved; however, their report included only five patients with cancer (8) . We also found increased total galactosyltransferase activity in three patients with renal insufficiency, as has been reported by Kirschbaum (13) , but did not detect isoenzyme II in these patients. The data presented in this study are compatible with the findings of Kim et al. (7) in regard to total serum galactosyltransferase activity (Fig. 1 ), but differ in that an isoenzyme of serum galactosyltransferase previously reported from this laboratory (9) In the cases studied, the incidence of false negatives appeared to be approximately 30% and only two cases of apparent false positives were found. As described above, one of the latter group had a constricting lesion of the sigmoid colon seen by x-ray but which was not found on laparotomy; however, tissue was not obtained to exclude carcinoma. The other patient had untreated active nontropical sprue (gluten-induced enteropathy), a condition known to be associated with increased mitotic activity of intestinal mucosal cells. The latter observation suggests that the presence of the isoenzyme II in serum may be a reflection of an increase in the number of cells undergoing cell division. It remains to be determined if isoenzyme II in celiac disease reflects increased cell division or is intrinsic to the disease.
The appearance of this unusual galactosyltransferase isoenzyme was not correlated with serum levels of alkaline phosphatase or with blood type. Kim et al. (14) had previously shown that serum N-acetyl-D-galactosaminyltransferase activity was found in individuals with blood groups A and AB but not in those with blood groups B or 0. However, they could not show any correlation of serum galactosyltransferase activity with blood type (2) . We also observed no correlation of blood type with either total serum galactosyltransferase activity or with galactosyltransferase isoenzymes. The levels of isoenzyme II appeared to be greater in patients with widespread metastases (Fig. 3) 
